June 7, 2013 -- SFL is pleased to announce that Shayesteh Fürst
-
Ladani
, Managing Director of the company,
has been invited as a panel member and give a presentation at the DIA 2012 49th Annual
Meeting to be held June 23
-
27 at the Boston Convention and Exhibition Center in Boston,
US.

Ms. Fürst
-
Ladani has been invited to spea
k at the session “Co
-
development of Targeted
Therapies and Companion Diagnostics: Identifying Regulatory Strategies to Overcome
Challenges” on Tuesday, June 25 at 1:45 pm
–
3:15 pm. In her presentation entitled
“European regulatory oversight of companion dia
gnostics”, Shayesteh will provide an
overview of the latest developments of the European legislation on companion diagnostics
(CDx) and explain potential implications for drug and IVD companies.

“This session will assist manufacturers in understanding the
regulatory changes taking place
for CDxs,” commented Shayesteh. “It will enable companies to learn about the practical
implications of the new regulatory framework and understand what will be expected of
them in the future in terms of meeting required stan
dards.

Shayesteh is the Managing Director and founder of SFL. She has comprehensive experience
in formulating global regulatory strategies and provides support for the development of
drugs, orphan drugs, drug and device combination products, borderline pr
oducts, medical
devices, in vitro diagnostics and advanced therapy medicinal products.

Shayesteh is Chair of the Combination Products Topic Group at EuropaBio. She has been
member of the Program Committee of DIA EuroMeeting for 2011, 2012, 2013 and 2014
le
ading the Theme Drugs, Devices, In Vitro Diagnostics and their Combinations. In 2012 she
received the Open University Business School’s Alumni Award Outstanding Contribution to
an Organization.